Drugs.com - Clinical Trials

Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil (Gemogenovatucel-T): An Investigational Personalized Immunotherapy for Advanced Ovarian Cancer

DALLAS, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Gradalis’ personalized...

Feb 9, 2025 - 21:44
 0
Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil (Gemogenovatucel-T): An Investigational Personalized Immunotherapy for Advanced Ovarian Cancer
DALLAS, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Gradalis’ personalized...
Read More

Tags:

Previous Article

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data for Isaralgage...

Next Article

Arbor Biotechnologies Announces FDA Orphan Drug and Rare Pediatric Disease Desig...

Related Posts

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics Receives Fast Track Designation for...

Feb 10, 2025  0

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

Nurix Therapeutics Receives U.S. FDA Fast Track Designa...

Feb 9, 2025  0

Boehringer’s Zongertinib Receives Priority Review from U.S. FDA for the Treatment of HER2 (ERBB2)-Mutant Advanced Non-Small Cell Lung Cancer

Boehringer’s Zongertinib Receives Priority Review from ...

Feb 20, 2025  0